ReportersNotebook — Chain Pharmacy, 10/24/11

SUPPLIER NEWS — The Medicines Co. and generic drug maker Teva Pharmaceutical Industries have reached a settlement that will allow Teva to start selling a generic version of one of MDCO’s drugs by the end of the decade. The drug makers announced the settlement in the U.S. District Court for the District of Delaware, whereby Teva can launch a generic version of the injectable anticoagulant drug Angiomax (bivalirudin) in June 2019.


Under the settlement, Teva admits that two patents covering Angiomax are valid, enforceable and would be infringed by Teva’s generic version. The patents are scheduled to expire in July 2028, according to the Food and Drug Administration. MDCO remains in infringement litigation concerning the drug with generic drug makers APP Pharmaceuticals, Hospira, Mylan and Dr. Reddy’s Labs.



Novo Nordisk
is seeking approval for two new insulin products, the company said. Novo Nordisk announced that it had filed with the Food and Drug Administration for approval of insulin degludec and a co-formulation of insulin degludec and insulin aspart. The products are insulin analogs developed for the treatment of Type 1 and Type 2 diabetes.



Amneal
last month launched its version of an epilepsy treatment. The drug maker said that felbamate tablets are available following approval from the Food and Drug Administration last month. The drug is the first-to-market generic equivalent of Meda Pharmaceuticals’ Felbatol, Amneal said.


The Amneal generic is available in 90-count bottles in 400-mg strength and 90- and 180-count sizes in 600-mg strength, the company said.


Annual U.S. sales of Felbatol totaled $43.7 million, according to IMS Health data.


Login or Register to post a comment.